PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 186 filers reported holding PDL BIOPHARMA INC in Q3 2017. The put-call ratio across all filers is 1.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $2,101,000 | +19.8% | 666,925 | +10.6% | 0.00% | 0.0% |
Q2 2020 | $1,754,000 | -2.7% | 602,936 | -5.7% | 0.00% | 0.0% |
Q1 2020 | $1,802,000 | -39.1% | 639,091 | -29.9% | 0.00% | 0.0% |
Q4 2019 | $2,959,000 | +42.3% | 911,858 | -5.3% | 0.00% | 0.0% |
Q3 2019 | $2,079,000 | -31.4% | 962,532 | -0.3% | 0.00% | 0.0% |
Q2 2019 | $3,032,000 | -34.6% | 965,447 | -22.6% | 0.00% | -50.0% |
Q1 2019 | $4,639,000 | -10.1% | 1,247,043 | -29.9% | 0.00% | 0.0% |
Q4 2018 | $5,162,000 | +25.0% | 1,779,928 | +13.3% | 0.00% | +100.0% |
Q3 2018 | $4,131,000 | +15.2% | 1,570,557 | +2.5% | 0.00% | 0.0% |
Q2 2018 | $3,587,000 | -20.2% | 1,532,880 | +0.3% | 0.00% | -50.0% |
Q1 2018 | $4,494,000 | +216.5% | 1,528,654 | +195.0% | 0.00% | +100.0% |
Q4 2017 | $1,420,000 | -76.6% | 518,274 | -71.1% | 0.00% | -50.0% |
Q3 2017 | $6,076,000 | +15.5% | 1,792,379 | -15.8% | 0.00% | 0.0% |
Q2 2017 | $5,259,000 | -2.9% | 2,129,184 | -10.7% | 0.00% | 0.0% |
Q1 2017 | $5,414,000 | +12.1% | 2,385,448 | +4.8% | 0.00% | 0.0% |
Q4 2016 | $4,828,000 | -43.3% | 2,277,053 | -10.5% | 0.00% | -33.3% |
Q3 2016 | $8,519,000 | -6.4% | 2,543,010 | -12.3% | 0.00% | 0.0% |
Q2 2016 | $9,101,000 | -12.4% | 2,898,520 | -7.1% | 0.00% | -25.0% |
Q1 2016 | $10,387,000 | -4.1% | 3,119,580 | +2.0% | 0.00% | 0.0% |
Q4 2015 | $10,832,000 | -53.8% | 3,059,760 | -34.3% | 0.00% | -60.0% |
Q3 2015 | $23,443,000 | -16.3% | 4,660,314 | +7.0% | 0.01% | -9.1% |
Q2 2015 | $28,000,000 | -6.5% | 4,354,603 | +2.3% | 0.01% | -8.3% |
Q1 2015 | $29,949,000 | +8.5% | 4,257,268 | +18.9% | 0.01% | +9.1% |
Q4 2014 | $27,605,000 | +44.4% | 3,580,540 | +39.9% | 0.01% | +37.5% |
Q3 2014 | $19,119,000 | -36.7% | 2,559,427 | -18.0% | 0.01% | -33.3% |
Q2 2014 | $30,222,000 | +11.9% | 3,122,197 | -3.9% | 0.01% | +9.1% |
Q1 2014 | $27,003,000 | +27.2% | 3,249,417 | +29.2% | 0.01% | +37.5% |
Q4 2013 | $21,226,000 | +42.0% | 2,514,877 | +34.1% | 0.01% | +33.3% |
Q3 2013 | $14,949,000 | +47.1% | 1,875,542 | +42.5% | 0.01% | +20.0% |
Q2 2013 | $10,162,000 | – | 1,316,424 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |